Resveratrol docks onto four ovarian cancer proteins - but clinical evidence remains distant
A new review uses molecular docking to show resveratrol binds four key ovarian cancer-associated proteins with strong affinity. But no direct clinical trials in ovarian cancer exist yet, and the compound's poor bioavailability remains a major hurdle.